Tax Software Specialist Vertex In Buy Zone After Base Breakout Vertex (NASDAQ:VERX) reported first-quarter 2026 results above ...

Vertex remains a Buy as its tax compliance software business shows resilience amid broad SaaS sector weakness. Read more on ...

Good morning, and welcome to the Vertex First Quarter 2026 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. If you have any objections, please disconnect at ...

The firm made the announcements as part of its Q1 financial report, in which it posted $2.99 billion in revenue, up 8 percent ...

Vertex Pharmaceuticals halted a cystic fibrosis program in the works with Moderna over lung inflammation concerns. The ...

After pausing a trial for a Moderna-partnered cystic fibrosis candidate due to subpar tolerability, Vertex Pharmaceuticals ...

King of Prussia-based Vertex plans to reduce its workforce by nine percent, as the tax and compliance software maker pivots ...

Given the rapidly evolving landscape of Artificial Intelligence, one of the biggest hurdles tech leaders often come across is transitioning from being “experimental” to being “enterprise-ready”. While ...

October 7, 2025—Jupiter Endovascular, Inc. announced it has closed a Series B financing round that surpassed its $40 million target. According to the company, the funds will be used to complete ...

The acquisition of Adams marks Vertex’s seventh acquisition under Wind Point ownership Jeff Christmann serves as CEO of Adams The Vertex Companies, a portfolio company of Wind Point Partners, has ...

Boston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR Therapeutics to develop the first CRISPR treatment approved by the U.S.

KING OF PRUSSIA, June 10, 2025 (GLOBE NEWSWIRE) -- Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced it has been selected to ...